Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial

J Neuroimaging. 2005 Jul;15(3):289-90. doi: 10.1177/1051228405277339.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase IV
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Contrast Media / administration & dosage*
  • Contrast Media / adverse effects
  • Drug Administration Schedule
  • Gadolinium DTPA / administration & dosage*
  • Gadolinium DTPA / adverse effects
  • Glatiramer Acetate
  • Humans
  • Interferon beta-1b
  • Interferon-beta / therapeutic use
  • Magnetic Resonance Imaging*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology*
  • Peptides / therapeutic use
  • Safety

Substances

  • Adjuvants, Immunologic
  • Contrast Media
  • Peptides
  • Interferon beta-1b
  • Glatiramer Acetate
  • Interferon-beta
  • Gadolinium DTPA